Research shows that one in four people diagnosed with pancreatic cancer were first diagnosed with Type 2 diabetes. For the millions of people with new-onset Type 2 diabetes who are potentially at risk for pancreatic cancer, early pancreatic cancer detection could help prevent a late-stage cancer, when treatments are limited or ineffective.

With multiple publications demonstrating the feasibility and validity of Bluestar Genomics’ test, the FDA granted it breakthrough device designation, supporting our novel approach to detecting the deadliest cancers.

With the prevalence of diabetes increasing worldwide, it is estimated that by 2025, more than 37 million patients will have been diagnosed with diabetes in the U.S. With such growing prevalence, it is imperative that we change the paradigm of late diagnosis depriving patients of effective treatments.